JP2000510858A - 6―フルオロウルソデオキシコール酸(6―fudca)による結腸直腸癌の予防および治療 - Google Patents
6―フルオロウルソデオキシコール酸(6―fudca)による結腸直腸癌の予防および治療Info
- Publication number
- JP2000510858A JP2000510858A JP09541562A JP54156297A JP2000510858A JP 2000510858 A JP2000510858 A JP 2000510858A JP 09541562 A JP09541562 A JP 09541562A JP 54156297 A JP54156297 A JP 54156297A JP 2000510858 A JP2000510858 A JP 2000510858A
- Authority
- JP
- Japan
- Prior art keywords
- fudca
- colon
- pharmaceutically acceptable
- acid
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.腺腫または微小腺腫を発生する危険性のある哺乳動物において、結腸腺腫ま たは結腸微小腺腫の少なくとも一方の発生率を減少するかまたはこれらを予防す る、または哺乳動物における糞便中デオキシコール酸を減少させるために使用す る医薬組成物の製造における、6−フルオロウルソデオキシコール酸(6−FU DCA)、医薬的に許容される6−FUDCAの塩、および医薬的に許容される 6−FUDCAの抱合体からなる群から選択された有効成分の使用。 2.腺腫または微小腺腫を発生する危険性のある哺乳動物における、結腸腺腫ま たは結腸微小腺腫の少なくとも一方の発生率を減少するかまたはこれらを予防す るために使用する医薬組成物の製造における、6−フルオロウルソデオキシコー ル酸(6−FUDCA)、医薬的に許容される6−FUDCAの塩、および医薬 的に許容される6−FUDCAの抱合体からなる群から選択された有効成分の、 請求項1に記載の使用。 3.哺乳動物の糞便中デオキシコール酸を減少させるために使用する医薬組成物 の製造における、6−フルオロウルソデオキシコール酸(6−FUDCA)、医 薬的に許容される6−FUDCAの塩、および医薬的に許容される6−FUDC Aの抱合体からなる群から選択された有効成分の、請求項1に記載の使用。 4.6−フルオロウルソデオキシコール酸(6−FUDCA)、医薬的に許容さ れる6−FUDCAの塩、および医薬的に許容される6−FUDCAの抱合体か らなる群から選択された有効成分の腺腫または微小腺腫予防または発生率減少量 を該哺乳動物に投与することを含む、腺腫または微小腺腫を発生する危険性のあ る哺乳動物における、結腸腺腫または結腸微小腺腫の少なくとも一方の発生率の 減少またはこれらの予防のための方法。 5.哺乳動物に、6−FUDCA、医薬的に許容される6−FUDCAの塩、お よび医薬的に許容される6−FUDCAの抱合体からなる群から選択された有効 成分の糞便中デオキシコール酸減少有効量を投与することを含む、哺乳動物の糞 便中デオキシコール酸の減少法。 6.該哺乳動物を、家畜、家庭のペット、およびヒトから選択する、請求項1− 5のいずれか1つに記載の使用または方法。 7.該哺乳動物がヒトである、請求項1−5のいずれか1つに記載の使用または 方法。 8.該有効成分が遊離6−FUDCAである、請求項1−5のいずれか1つに記 載の使用または方法。 9.該有効量が、遊離6−FUDCAに基づいて計算した経口投与にして約1mg /kg/日から約30mg/kg/日である請求項4または5に記載の方法。 10.該有効量が、約5mg/kg/日から約8mg/kg/日である請求項4または5に記 載の方法。 11.該有効成分の該1日量を1から4回の分割用量で投与する、請求項4また は5に記載の方法。 12.該有効成分の該1日量を2から3回の分割用量で投与する、請求項4また は5に記載の方法。 13.(a)結腸癌、結腸腺腫、および結腸微小腺腫の少なくとも1つであると 診断された;および/または (b)結腸癌、結腸腺腫、結腸微小腺腫、および結腸ポリープの少なくとも1つ であると診断された近い血族を有する哺乳動物から、結腸腺腫および/または結 腸微小腺腫を発生する危険性がある該哺乳動物を選択する、請求項1−5のいず れか1つに記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1820296P | 1996-05-23 | 1996-05-23 | |
US60/018,202 | 1996-05-23 | ||
PCT/EP1997/002632 WO1997044043A1 (en) | 1996-05-23 | 1997-05-22 | Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca) |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009252071A Division JP2010059175A (ja) | 1996-05-23 | 2009-11-02 | 6−フルオロウルソデオキシコール酸(6−fudca)を含む結腸腺腫または結腸微小腺腫の処置または進行の遅延用医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000510858A true JP2000510858A (ja) | 2000-08-22 |
JP2000510858A5 JP2000510858A5 (ja) | 2004-12-09 |
Family
ID=21786767
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09541562A Pending JP2000510858A (ja) | 1996-05-23 | 1997-05-22 | 6―フルオロウルソデオキシコール酸(6―fudca)による結腸直腸癌の予防および治療 |
JP2009252071A Withdrawn JP2010059175A (ja) | 1996-05-23 | 2009-11-02 | 6−フルオロウルソデオキシコール酸(6−fudca)を含む結腸腺腫または結腸微小腺腫の処置または進行の遅延用医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009252071A Withdrawn JP2010059175A (ja) | 1996-05-23 | 2009-11-02 | 6−フルオロウルソデオキシコール酸(6−fudca)を含む結腸腺腫または結腸微小腺腫の処置または進行の遅延用医薬組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6426340B1 (ja) |
EP (1) | EP0906106B1 (ja) |
JP (2) | JP2000510858A (ja) |
AT (1) | ATE394107T1 (ja) |
AU (1) | AU3091597A (ja) |
CA (1) | CA2253593C (ja) |
DE (1) | DE69738667D1 (ja) |
ES (1) | ES2306459T3 (ja) |
PT (1) | PT906106E (ja) |
WO (1) | WO1997044043A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1113785B1 (en) * | 1998-07-24 | 2005-04-13 | Seo Hong Yoo | Clear aqueous solutions of bile acids |
EP1105141B1 (de) * | 1998-08-06 | 2003-11-05 | Wolfgang Stremmel | Phosphatidylcholin als arzneimittel mit schleimhautschützender wirkung |
RS50303B (sr) * | 1999-09-28 | 2009-09-08 | Panacea Biotec Limited, | Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem |
US7053076B2 (en) | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
AU2003287300A1 (en) * | 2002-11-01 | 2004-06-07 | James Kaput | Identification of diet-regulated disease-associated genes |
US20090074785A1 (en) * | 2007-01-16 | 2009-03-19 | Smith Jeffrey W | Compositions and methods for treatment of colorectal cancer |
EP2255813A1 (en) * | 2009-05-29 | 2010-12-01 | The Royal College of Surgeons in Ireland | Derivatives of ursodeoxycholic acid for the treatment of diarrhoea |
HUE030062T2 (en) | 2010-11-08 | 2017-04-28 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
BR112020024479A2 (pt) | 2018-06-20 | 2021-03-02 | Albireo Ab | hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
DK4069360T3 (da) | 2019-12-04 | 2024-02-26 | Albireo Ab | Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer |
ES2972045T3 (es) | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8825526D0 (en) * | 1988-11-01 | 1988-12-07 | Enzymatix Ltd | Diagnosis |
US5175320A (en) * | 1989-04-17 | 1992-12-29 | Giuliani S.P.A. | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
-
1997
- 1997-05-22 AU AU30915/97A patent/AU3091597A/en not_active Abandoned
- 1997-05-22 JP JP09541562A patent/JP2000510858A/ja active Pending
- 1997-05-22 CA CA002253593A patent/CA2253593C/en not_active Expired - Fee Related
- 1997-05-22 EP EP97925934A patent/EP0906106B1/en not_active Expired - Lifetime
- 1997-05-22 WO PCT/EP1997/002632 patent/WO1997044043A1/en active IP Right Grant
- 1997-05-22 PT PT97925934T patent/PT906106E/pt unknown
- 1997-05-22 AT AT97925934T patent/ATE394107T1/de not_active IP Right Cessation
- 1997-05-22 DE DE69738667T patent/DE69738667D1/de not_active Expired - Lifetime
- 1997-05-22 ES ES97925934T patent/ES2306459T3/es not_active Expired - Lifetime
-
2000
- 2000-10-06 US US09/684,585 patent/US6426340B1/en not_active Expired - Fee Related
-
2009
- 2009-11-02 JP JP2009252071A patent/JP2010059175A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
PT906106E (pt) | 2008-08-07 |
JP2010059175A (ja) | 2010-03-18 |
CA2253593A1 (en) | 1997-11-27 |
DE69738667D1 (de) | 2008-06-19 |
ES2306459T3 (es) | 2008-11-01 |
US6426340B1 (en) | 2002-07-30 |
CA2253593C (en) | 2008-07-08 |
AU3091597A (en) | 1997-12-09 |
EP0906106B1 (en) | 2008-05-07 |
WO1997044043A1 (en) | 1997-11-27 |
ATE394107T1 (de) | 2008-05-15 |
EP0906106A1 (en) | 1999-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2253593C (en) | Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca) | |
JP4297620B2 (ja) | 肝細胞性腫瘍処置用薬剤 | |
JP2001519774A (ja) | ホルモン性避妊及び/又は乳腺腫瘍の処置及び/又は予防用の薬剤、応用及び方法 | |
JP6753860B2 (ja) | リルゾールの舌下製剤 | |
WO1994022896A1 (en) | Cholestasis ameliorant | |
JPS6048924A (ja) | 骨粗鬆症治療剤 | |
JP2001520994A (ja) | 消化管疾患を治療するためにクマリン誘導体を用いる用途 | |
Mazzella et al. | Comparative evaluation of chenodeoxycholic and ursodeoxycholic acids in obese patients: effects on biliary lipid metabolism during weight maintenance and weight reduction | |
KR100450293B1 (ko) | 만성장염의치료에유용한알카노일l-카르니틴의용도 | |
JPH10507751A (ja) | 鉄およびジフルクトースを含有する抗貧血剤 | |
PL186377B1 (pl) | Kompozycja farmaceutyczna do leczenia chorób autoimmunologicznych | |
KR100730338B1 (ko) | γ-토코트리에놀 함유 이뇨제 | |
JP2007524651A (ja) | 多剤耐性遺伝子の発現を抑制して、該遺伝子の発現によって生じるタンパク質の製造を抑制し、それにより、癌治療のための化学療法薬の有効性を高める方法。 | |
US6677328B1 (en) | Method for the prevention of colonic adenomas | |
KR20030036640A (ko) | 만성 소화 장애증의 치료 방법 | |
JP2001505574A (ja) | 17α−ジヒドロエキレニンを使用した神経退化および認識機能障害の予防方法 | |
CN114040913B (zh) | 哒嗪酮trpc5抑制剂的喷雾干燥制剂 | |
Dowsett et al. | 0-73. Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer | |
JP2999539B2 (ja) | 白血球減少症の予防・治療剤 | |
US20040248859A1 (en) | Medicinal compositions for treating secondary parathyroid hyperfunction and remedies for cardiovascular complications in association with treatment for secondary parathyroid hyperfunction | |
CA2159354A1 (en) | Method and composition for treatment of osteoporosis | |
CN118634316A (zh) | 一种预防和治疗胆汁淤积症的司美格鲁肽联合用药组合物 | |
JPH04266822A (ja) | システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤 | |
US20040121991A1 (en) | Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers | |
JP2731063B2 (ja) | 卵巣欠落によるのぼせ治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040406 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080415 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080714 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080930 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081121 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090309 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090224 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090413 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091102 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091217 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100811 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100820 |